The Supreme Court Thursday sought response from the Centre on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.
The flu drug favipiravir has shown promise in preventing the coronavirus infection in rodents when administered in high doses, says a study.
Favivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at Rs 2,640 per pack, Hetero said in a statement.
Drug firm FDC Ltd on Tuesday said it has launched two variants of the COVID-19 drug Favipiravir under the brand names PiFLU and Favenza.
Dr Reddy's Laboratories has announced the launch of Avigan (Favipiravir) tablets, used for COVID-19 treatment, in India. The drug major said that Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19.
The tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenar's US FDA approved facility in Hyderabad, a press release from the drug maker said.
Drug firm BDR Pharmaceuticals on Wednesday said it has launched its antiviral drug Favipiravir for the treatment of COVID-19 patients in India at a price of Rs 63 per tablet.
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease, it added.
Favivir improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms.
Hyderabad-based Avra Laboratories Pvt Ltd announced on Monday that it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir Active Pharmaceutical Ingredient (API) for treatment of COVID-19.
The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution.
Pharmaceutical firm Cipla is set to launch COVID-19 drug Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process. Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India.
Glenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
According to Glenmark, 40 per cent faster achievement of "clinical cure" was witnessed in the third phase of the clinical trials of Favipiravir involving 150 patients with mild to moderate COVID-19 across seven clinical sites in India.
Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well. It has also received approval in Turkey in collaboration with a local Turkish partner.
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet. In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.
Maharashtra Chief Minister Uddhav Thackeray on Sunday said that the state government is planning to provide COVID-19 drugs, Remdesivir and Favipiravir, for free to people.
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
Shares of Glenmark Pharmaceuticals on Monday rallied 20 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Top News
Latest News
